Identificationof novel diagnostic and therapeutic factors for endocrine therapy-resistant breast cancer by next-generation sequencing strategy

点击翻译按钮获取中文摘要

To identify the novel diagnostic and therapeutic factors for endocrine therapy-resistant breast cancer, we focused on FOXP1, one of a forkhead transcription factor family, as a candidate, and its genome-wide distributionin ERα-positive breast cancer MCF-7 cells was examined by next-generation sequencing strategy. We demonstrated that majority of binding regions of FOXP1 in MCF-7 cells stimulated with estrogen were overlapped with those of both Erαand FOXA1. We also demonstrated that the double-positive immunoreactivities of FOXP1 and FOXA1 are significantly associated with a favorable prognosis for survival of breast cancer patients receiving adjuvant tamoxifen therapy. In this study, we revealed that, similar to FOXA1, FOXP1 is assumed to be a critical transcription factor for Erαsignaling, and both forkhead transcription factors can serve as predictive factors for acquired endocrine resistance in breast cancer.